Myelodysplastic Syndrome
📧 Sign up to get email alerts when something new happens for Myelodysplastic Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-02-12Clinical Trial Update: Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome [Phase 1, Phase 2]
A phase 1/2 clinical trial testing venetoclax in combination with azacitidine for high-risk recurrent or refractory myelodysplastic syndrome…
-
CLINICAL_TRIALS withdrawal · 2025-05-25Clinical Trial Update: Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor [Phase 1]
A Phase 1 study evaluating multi-antigen specific CD8+ T cells with decitabine and lymphodepleting chemotherapy for relapsed or refractory a…
-
CLINICAL_TRIALS withdrawal · 2025-04-22Clinical Trial Update: Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction [Phase 2]
Phase 2 frontline trial evaluating cladribine/low-dose cytarabine alternating with decitabine versus hypomethylating agents plus venetoclax …
-
CLINICAL_TRIALS withdrawal · 2024-12-05Clinical Trial Update: A Study of FF-10501-01 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome [Phase 2]
A Phase 2 study of FF-10501-01 in combination with azacitidine for myelodysplastic syndrome has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-12-05Clinical Trial Update: Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT [Phase 1]
A Phase 1 trial evaluating a preemptive infusion of donor lymphocytes depleted of TCR+ T cells and CD19+ B cells after autologous stem cell …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2024-09-19Clinical Trial Update: Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS [Phase 1]
A Phase 1 trial of magrolimab in combination with azacitidine after allogeneic hematopoietic cell transplantation in high-risk acute myeloid…
-
CLINICAL_TRIALS withdrawal · 2021-04-27Clinical Trial Update: Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT [Phase 3]
Phase 3 randomized trial evaluating standard of care with or without atorvastatin for prevention of graft-versus-host disease in matched unr…
-
CLINICAL_TRIALS withdrawal · 2018-07-26Clinical Trial Update: Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study [NA]
A pilot clinical trial on patient-driven transfusion thresholds in hematological disorders sponsored by Emory University has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-03-14Clinical Trial Update: Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment [Phase 2]
Clinical trial update notes that a Phase 2 study evaluating the pharmacokinetics and pharmacodynamics of CPX-351 in acute leukemias and myel…
-
CLINICAL_TRIALS withdrawal · 2016-12-29Clinical Trial Update: Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome [Phase 2]
A Phase 2 trial evaluating CPI-613 for refractory or relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-07-30Clinical Trial Update: NOV-002 in Myelodysplastic Syndrome (MDS) [Phase 2]
Phase 2 trial of NOV-002 in myelodysplastic syndrome has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-05-10Clinical Trial Update: Palifermin After Haploidentical PBSCT [Phase 2]
A Phase 2 trial evaluating palifermin after haploidentical peripheral blood stem cell transplantation has been withdrawn.